Compounded Tirzepatide Alternatives in Michigan
Compare generic and therapeutic alternatives to Compounded Tirzepatide (tirzepatide (compounded)) available at Michigan pharmacies. Save up to 71% on your prescription — no insurance required.
Top Alternatives in Michigan
Mounjaro (brand tirzepatide)
brand
FDA-approved injectable tirzepatide — 3× more expensive
Avg cash price: $1020/mo
Zepbound (tirzepatide for weight loss)
brand
Weight-loss FDA indication of tirzepatide
Avg cash price: $1060/mo
Compounded semaglutide
therapeutic
GLP-1 compounded alternative — available from similar pharmacies
Avg cash price: $250/mo
Michigan Prescription Assistance Programs
Michigan Medicaid Rx
Prescription drug coverage for Michigan Medicaid beneficiaries through managed care organizations.
Eligibility: Low-income Michigan adults up to 138% FPL (via Healthy Michigan Plan), plus children and people with disabilities.
Frequently Asked Questions
Is compounded tirzepatide the same as Mounjaro?
Compounded tirzepatide contains the same active molecule as Mounjaro/Zepbound but is produced by compounding pharmacies, not Eli Lilly. It is not FDA-approved as a finished product.
How much cheaper is compounded tirzepatide vs Mounjaro?
Compounded tirzepatide typically costs $250–$400/month versus $1,000+ for brand Mounjaro — a saving of 60–75%.
Can I still get compounded tirzepatide in 2025?
Availability depends on whether tirzepatide remains on the FDA drug shortage list. Compounding is only legal during active shortages. Confirm current status with your pharmacist.
How does compounded tirzepatide compare to compounded semaglutide?
Both are GLP-1-based weight-loss injectables. Tirzepatide additionally targets GIP receptors, which in trials produced slightly greater average weight loss. Both are available at similar compounding prices.
How do I access compounded tirzepatide through Script Unlock?
Post your tirzepatide prescription on Script Unlock. Licensed compounding pharmacies in the network will indicate availability and submit cash-price bids.